Categories: HealthcareNews

Philips completes cancellation of 4.4 million shares

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

June 19, 2024

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 4,437,164 of its shares. The cancelled shares were acquired as part of the completed EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021.

Philips’ current issued share capital amounts to EUR 187,987,876.80 representing 939,939,384 common shares.

More information is available here

For further information, please contact:

Ben Zwirs
Philips External Relations
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,100 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Staff

Recent Posts

The Future of Ultrasound Reporting 

By Cecile Brosset, CEO of Sonio The landscape of ultrasound technology is rapidly evolving, driven…

10 hours ago

Beyond Medical Technologies Announces $2.5 Million Convertible Note Financing to Support Blockchain Attestation Platform

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…

10 hours ago

Albert Einstein College of Medicine Launches Data Science Institute

Leveraging the Power of Data to Accelerate Scientific Discovery and Improve Health in the Bronx…

10 hours ago

Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World

SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Plasmidsaurus, the company that…

10 hours ago

Trusted by healthcare leaders: Medical Solutions earns Top 10 MSP spot for fourth year

OMAHA, Neb., May 6, 2025 /PRNewswire/ -- Medical Solutions, one of the nation's largest and most…

10 hours ago

AliveCor Launches AI-Powered KardiaMobile 6L Max and KardiaAlert to Deliver the Most Advanced Personal ECG Solution on the Market

KardiaMobile 6L Max is powered by advanced AI to offer a wider range of arrhythmia…

10 hours ago